Correlation research between sTIM-3 and its ligands Gal-9, HMGB1 in patients with type 2 diabetes complicated with coronary heart disease

doi:10.11958/20221307

Abstract

CLC Number:

R392.6

Figures/Tables 5

References 23

[1]	GUO J, SMITH S M. Newer drug treatments for type 2 diabetes[J]. BMJ, 2021, 373:n1171. doi:10.1136/bmj.n1171.
[2]	THOMAS M C. Type 2 diabetes and heart failure:Challenges and solutions[J]. Curr Cardiol Rev, 2016, 12(3): 249-255. doi:10.2174/1573403x12666160606120254.
[3]	DIXON K O, DAS M, KUCHROO V K. Human disease mutations highlight the inhibitory function of TIM-3[J]. Nat Genet, 2018, 50(12):1640-1641. doi:10.1038/s41588-018-0289-3.
[4]	GROSSMAN T B, MINIS E, LOEB-ZEITLIN S E, et al. Soluble T cell immunoglobulin mucin domain 3(sTim-3)in maternal sera:A potential contributor to immune regulation during pregnancy[J]. J Matern Fetal Neonatal Med, 2021, 34(24):4119-4122. doi:10.1080/14767058.2019.1706471.
[5]	HASTINGS W D, ANDERSON D E, KASSAM N, et al. TIM-3 is expressed on activated human CD4⁺ T cells and regulates Th1 and Th17 cytokines[J]. Eur J Immunol, 2009, 39:2492-2501. doi:10.1002/eji.200939274.
[6]	CHEN S, DONG Z, YANG P, et al. Hepatitis B virus X protein stimulates high mobility group box 1 secretion and enhances hepatocellular carcinoma metastasis[J]. Cancer Lett, 2017, 394:22-32. doi:10.1016/j.canlet.2017.02.011.
[7]	钟玉梅, 陈洋, 罗小超, 等. Tim-3调控巨噬细胞极化在类风湿性关节炎中的研究进展[J]. 天津医药, 2020, 48(9):898-902.
	ZHONG Y M, CHEN Y, LUO X C, et al. Research progress of Tim-3 regulating the polarization of macrophage in rheumatoid arthritis[J]. Tianjin Med J, 2020, 48(9):898-902. doi:10.11958/20200625.
[8]	KAMATA Y, TAKANO K, KISHIHARA E, et al. Distinct clinical characteristics and therapeutic modalities for diabetic ketoacidosis in type 1 and type 2 diabetes mellitus[J]. J Diabetes Complications, 2017, 31(2):468-472. doi:10.1016/j.jdiacomp.2016.06.023.
[9]	NYAMBUYA T M, DLUDLA P V, MXINWA V, et al. T-cell activation and cardiovascular risk in adults with type 2 diabetes mellitus:A systematic review and meta-analysis[J]. Clin Immunol, 2020, 210:108313. doi:10.1016/j.clim.2019.108313.
[10]	WANG H, CAO K, LIU S, et al. Tim-3 expression causes NK cell dysfunction in type 2 diabetes patients[J]. Front Immunol, 2022, 13:852436. doi:10.3389/fimmu.2022.852436.
[11]	石新慧. 可溶性Tim-3在疾病中的表达及其意义的研究[D]. 北京: 中国人民解放军军事医学科学院基础医学研究所, 2016.
	SHI X H. Expression and clinical significance of soluble Tim-3 in different diseases[D]. Beijing: Institute of Basic Medical Sciences, Academy of Military Medical Sciences, 2016.
[12]	ZHANG J, ZHAN F, LIU H L. Expression level and significance of Tim-3 in CD4+ T lymphocytes in peripheral blood of patients with coronary heart disease[J]. Braz J Cardiovasc Surg, 2022, 37(3):350-355. doi:10.21470/1678-9741-2020-0509.
[13]	HOU N, ZHAO D, LIU Y, et al. Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis[J]. Atherosclerosis, 2012, 222(1):67-73. doi:10.1016/j.atherosclerosis.2012.02.009.
[14]	HAO H, HE M, LI J, et al. Upregulation of the Tim-3/Gal-9 pathway and correlation with the development of preeclampsia[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 194:85-91. doi:10.1016/j.ejogrb.2015.08.022.
[15]	HIRASHIMA M, KASHIO Y, NISHI N, et al. Galectin-9 in physiological and pathological conditions[J]. Glycoconj J, 2002, 19(7/8/9):593-600. doi:10.1023/B:GLYC.0000014090.63206.2f.
[16]	SAKAI K, KAWATA E, ASHIHARA E, et al. Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis[J]. Eur J Immunol, 2011, 41(1):67-75. doi:10.1002/eji.200939931.
[17]	MANSOUR A A, RAUCCI F, SAVIANO A, et al. Galectin-9 regulates monosodium urate crystal-induced gouty inflammation through the modulation of Treg/Th17 ratio[J]. Front Immunol, 2021, 12:762016. doi:10.3389/fimmu.2021.762016.
[18]	SUN L, ZOU S, DING S, et al. Circulating T cells exhibit different TIM3/Galectin-9 expression in patients with obesity and obesity-related diabetes[J]. J Diabetes Res, 2020, 2020:2583257. doi:10.1155/2020/2583257.
[19]	KUROSE Y, WADA J, KANZAKI M O, et al. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease[J]. BMC Nephrol, 2013, 14:23. doi:10.1186/1471-2369-14-23.
[20]	SU Z, WANG T, ZHU H, et al. HMGB1 modulates Lewis cell autophagy and promotes cell survival via RAGE-HMGB1-Erk1/2 positive feedback during nutrient depletion[J]. Immunobiology, 2015, 220(5):539-544. doi:10.1016/j.imbio.2014.12.009.
[21]	BEHL T, SHARMA E, SEHGAL A, et al. Expatiating the molecular approaches of HMGB1 in diabetes mellitus:Highlighting signalling pathways via RAGE and TLRs[J]. Mol Biol Rep, 2021, 48(2):1869-1881. doi:10.1007 /s11033-020-06130-x.
[22]	CHEN Y, QIAO F, ZHAO Y, et al. HMGB1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucose[J]. Int J Clin Exp Pathol, 2015, 8(6):6683-6691.
[23]	BENLIER N, ERDOĞAN M B, KEÇIOĞLU S, et al. Association of high mobility group box 1 protein with coronary artery disease[J]. Asian Cardiovasc Thorac Ann, 2019, 27(4):251-255. doi:10.1177/0218492319835725.

组别	n	男性	年龄（岁）	BMI（kg/m²）	FBG（mmol/L）	HbA1c（%）
Con组	48	23（47.9）	51.00（47.00，55.00）	22.05±3.37	5.19（4.88，5.57）	4.80（4.43，5.20）
T2DM组	50	26（52.0）	51.50（47.75，58.25）	25.15±3.07^a	9.68（8.15，11.63）^a	8.67（7.88，9.49）^a
T2DM+CHD组	52	25（48.1）	51.00（47.00，58.00）	26.64±3.58^ab	12.25（8.86，15.92）^a	9.00（7.33，11.45）^a
χ²/F		0.214	0.780	24.245^＊＊	102.050^＊＊	97.268^＊＊

组别	n	男性	年龄（岁）	BMI（kg/m²）	FBG（mmol/L）	HbA1c（%）
Con组	48	23（47.9）	51.00（47.00，55.00）	22.05±3.37	5.19（4.88，5.57）	4.80（4.43，5.20）
T2DM组	50	26（52.0）	51.50（47.75，58.25）	25.15±3.07^a	9.68（8.15，11.63）^a	8.67（7.88，9.49）^a
T2DM+CHD组	52	25（48.1）	51.00（47.00，58.00）	26.64±3.58^ab	12.25（8.86，15.92）^a	9.00（7.33，11.45）^a
χ²/F		0.214	0.780	24.245^＊＊	102.050^＊＊	97.268^＊＊

组别	n	sTIM-3（ng/L）	Gal-9（ng/L）	HMGB1（ng/L）
Con组	48	169.31（149.28，187.71）	361.47±76.92	823.73（757.03，901.77）
T2DM组	50	203.95（169.46，240.09）^a	407.37±52.80^a	940.95（857.03，1 019.66）^a
T2DM+CHD组	52	252.81（199.47，330.65）^ab	441.36±76.84^ab	998.39（879.48，1 087.47）^a
F		43.253^＊＊	16.522^＊＊	34.700^＊＊

组别	n	sTIM-3（ng/L）	Gal-9（ng/L）	HMGB1（ng/L）
Con组	48	169.31（149.28，187.71）	361.47±76.92	823.73（757.03，901.77）
T2DM组	50	203.95（169.46，240.09）^a	407.37±52.80^a	940.95（857.03，1 019.66）^a
T2DM+CHD组	52	252.81（199.47，330.65）^ab	441.36±76.84^ab	998.39（879.48，1 087.47）^a
F		43.253^＊＊	16.522^＊＊	34.700^＊＊

变量	AUC（95%CI）	敏感度（%）	特异度（%）	截断值（ng/L）	约登指数
sTIM-3	0.794（0.722~0.867）	62.75	87.50	204.28	0.50
Gal-9	0.735（0.651~0.820）	50.00	85.42	422.41	0.35
联合诊断	0.812（0.743~0.882）	67.65	83.33	—	0.51

Correlation research between sTIM-3 and its ligands Gal-9, HMGB1 in patients with type 2 diabetes complicated with coronary heart disease

Cite this article

RichHTML

PDF (PC)

Knowledge

Abstract

share this article

Figures/Tables 5

References 23

Related Articles 15

Recommended Articles

Metrics

Comments

因素	β	SE	Wald χ²	P	OR（95%CI）
BMI	0.213	0.062	11.690	0.001	1.237（1.095，1.833）
年龄	0.022	0.023	0.874	0.350	1.022（0.976，1.070）
sTIM-3	0.013	0.004	8.287	0.004	1.013（1.004，1.021）
Gal-9	0.007	0.004	3.870	0.049	1.007（1.000，1.015）
HMGB1	-0.001	0.002	0.193	0.660	0.999（0.996，1.002）
常数项	-12.300	2.777	19.620	<0.001	<0.001

[1]	GU Yunyun, ZHONG Chongming, YANG Haiyan. Predictive value of uric acid/albumin ratio for coronary heart disease in patients with chronic kidney disease [J]. Tianjin Medical Journal, 2024, 52(11): 1202-1206.
[2]	LIU Shouhong, ZHANG Yongquan, WANG Qiao. Correlation between serum ficolin and coronary artery stenosis and its influence on prognosis in patients with coronary heart disease [J]. Tianjin Medical Journal, 2023, 51(7): 776-780.
[3]	LIU Yuanyuan, ZHANG Enyuan, WANG Chengjian, YANG Shicheng, SI Hailong, XUE Yuanyuan, ZHENG Junyi. Clinical effect of Qishen Yiqi dropping pill on the prognosis of patients with depression after percutaneous coronary intervention [J]. Tianjin Medical Journal, 2023, 51(5): 508-512.
[4]	HAN Chuyi, CONG Hongliang, WANG Le, ZHANG Jingxia. Prediction of risk factors for hypothyroidism in NSTE-ACS patients exposed to iodine contrast media [J]. Tianjin Medical Journal, 2023, 51(4): 422-426.
[5]	LU Rongzhen, HUANG Jiangnan, PAN Xingshou, LU Ting, LI Jindu, LI Tianzi, TAN Shuhan. Application effect research of different antihypertensive modes in elderly hypertensive patients with coronary heart disease and PCI [J]. Tianjin Medical Journal, 2023, 51(3): 277-281.
[6]	LIU Yixiang, FAN Wenjun, DING Zhenjiang, ZHANG Ying, SHI Fei, LIU Jingyi, SUN Lixian. The diagnostic values of WMR, MLR and their combination in the severity of coronary artery disease [J]. Tianjin Medical Journal, 2022, 50(8): 859-862.
[7]	YAN Yu, WANG Xiaowen, GU Yumeng, XUE Juanjuan, XIA Xiaoshuang, WANG Lin, LI Xin, △. Relationship between blood pressure variability and ambient temperature variation in patients with hypertension complicated with acute ischemic stroke [J]. Tianjin Medical Journal, 2022, 50(6): 627-632.
[8]	GONG Zhaohui, ZHAO Xinjun, LUO Chuanjin, CHU Qingmin, WU Wei, LI Rong△. Study on the macrophage apoptosis and M1/M2 polarization in patients with different types of coronary heart disease [J]. Tianjin Medical Journal, 2022, 50(5): 503-508.
[9]	ZHANG Ying, SHAO Dujing, LIU Xiaogang, ZHAO Yingqiang, LIU Yujie . Clinical study of cardiovascular protective effect of Qishen yiqi dropping pills on patients with hypertension complicated by coronary heart disease #br# [J]. Tianjin Medical Journal, 2022, 50(2): 177-181.
[10]	SONG Zhi-yong, JIANG Chao, LUO Dong-lei, YAO Yan-ying, ZHANG Lei, LIU Lei, HOU Yun-sheng. The effect of pre-test probability combined with radionuclide myocardial perfusion imaging on the diagnosis of coronary heart disease in different genders [J]. Tianjin Medical Journal, 2021, 49(8): 870-874.
[11]	XIE Meng-li, SU Jing, LI Jing, HAN Yi. Changes of serum nociceptin/orphanin FQ and lipoprotein‐associated phospholipase A2 levels in diabetic patients with silent myocardial ischemia [J]. Tianjin Medical Journal, 2021, 49(4): 390-395.
[12]	ZHUHui-jie, ZHANGYing△, LIUYu-jie, ZHOUJia. The comparison of the risk stratification and diagnostic strategy of stable chest pain guided by NICE and ESC guidelines by using coronary CT angiography [J]. Tianjin Medical Journal, 2021, 49(3): 310-314.
[13]	ZHAO Jie, LI Shu-ying, ZHANG Ying, SHAN Wei-chao, ZHANG Hao-ran, HAN Leng, DING Zhen-jiang△. Correlation analysis of different subtypes of LDL and AIP in young and middle-aged and elderly patients with coronary heart disease [J]. Tianjin Medical Journal, 2021, 49(1): 54-58.
[14]	NI Yue, JIANG Jun, PENG Yan-fei, SHI Lei-zhong. Correlation between plasma neutrophil gelatinase-associated lipocalin and severity of coronary heart disease#br# [J]. Tianjin Medical Journal, 2021, 49(1): 50-53.
[15]	PENG Ming, LI Yu-kai, WANG Lan, XIAO Jie, CHENG Zhong△. The influence of coronary heart disease on the development and prognosis of COVID-19 patients [J]. Tianjin Medical Journal, 2020, 48(7): 599-602.